Chung‐Pin Li

8.0k total citations
170 papers, 4.5k citations indexed

About

Chung‐Pin Li is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Chung‐Pin Li has authored 170 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 55 papers in Epidemiology and 46 papers in Surgery. Recurrent topics in Chung‐Pin Li's work include Pancreatic and Hepatic Oncology Research (53 papers), Neuroendocrine Tumor Research Advances (24 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers). Chung‐Pin Li is often cited by papers focused on Pancreatic and Hepatic Oncology Research (53 papers), Neuroendocrine Tumor Research Advances (24 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers). Chung‐Pin Li collaborates with scholars based in Taiwan, United States and South Korea. Chung‐Pin Li's co-authors include Yee Chao, Chen‐Yi Wu, Hsiao‐Yun Hu, Nicole Huang, Yiing‐Jenq Chou, Shou‐Dong Lee, Han‐Chieh Lin, Jiing‐Chyuan Luo, Rheun‐Chuan Lee and Shinn‐Jang Hwang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Chung‐Pin Li

163 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chung‐Pin Li Taiwan 35 1.8k 1.0k 997 856 780 170 4.5k
Zhenqiu Liu China 29 1.3k 0.7× 1.1k 1.1× 1.3k 1.3× 433 0.5× 755 1.0× 134 4.1k
Ioannis Ntanasis‐Stathopoulos Greece 35 2.0k 1.1× 589 0.6× 1.3k 1.3× 713 0.8× 410 0.5× 268 5.9k
Bernd Kremer Netherlands 42 2.0k 1.1× 651 0.6× 912 0.9× 1.8k 2.1× 526 0.7× 157 5.1k
Diamantis I. Tsilimigras United States 36 2.2k 1.2× 891 0.9× 601 0.6× 2.2k 2.5× 440 0.6× 305 5.4k
David L. Cutler United States 31 888 0.5× 737 0.7× 938 0.9× 503 0.6× 344 0.4× 145 3.9k
Dimitrios Moris Greece 39 1.8k 1.0× 985 1.0× 963 1.0× 2.9k 3.4× 623 0.8× 332 6.2k
Hugh Mulcahy Ireland 45 2.6k 1.4× 1.0k 1.0× 1.5k 1.5× 2.1k 2.4× 1.2k 1.6× 204 6.9k
Ardeshir Ghavamzadeh Iran 36 1.0k 0.6× 492 0.5× 2.3k 2.3× 1.1k 1.3× 605 0.8× 363 6.5k
Irene Helenowski United States 39 1.7k 0.9× 683 0.7× 898 0.9× 877 1.0× 563 0.7× 232 5.7k
Emanuela Scarpi Italy 46 3.5k 1.9× 754 0.7× 1.2k 1.2× 886 1.0× 1.4k 1.9× 265 7.0k

Countries citing papers authored by Chung‐Pin Li

Since Specialization
Citations

This map shows the geographic impact of Chung‐Pin Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chung‐Pin Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chung‐Pin Li more than expected).

Fields of papers citing papers by Chung‐Pin Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chung‐Pin Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chung‐Pin Li. The network helps show where Chung‐Pin Li may publish in the future.

Co-authorship network of co-authors of Chung‐Pin Li

This figure shows the co-authorship network connecting the top 25 collaborators of Chung‐Pin Li. A scholar is included among the top collaborators of Chung‐Pin Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chung‐Pin Li. Chung‐Pin Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Su, Yung‐Yeh, Nai‐Jung Chiang, Yi‐Hsin Yang, et al.. (2023). Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Cancers. 15(4). 1008–1008. 5 indexed citations
2.
Su, Yung‐Yeh, Nai‐Jung Chiang, Tai‐Jan Chiu, et al.. (2023). Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Biomedical Journal. 47(3). 100696–100696. 1 indexed citations
3.
Lirng, Jiing-Feng, Tzu‐Hao Li, Chia‐Chang Huang, et al.. (2023). Negative effects on medical students’ scores for clinical performance during the COVID-19 pandemic in Taiwan: a comparative study. Journal of Educational Evaluation for Health Professions. 20. 37–37.
4.
5.
Li, Chung‐Pin, Yi‐Hsiang Huang, Shao‐Jung Hsu, et al.. (2022). Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers. 14(1). 218–218. 15 indexed citations
6.
Lee, I‐Cheng, Keng‐Hsin Lan, Chien‐Wei Su, et al.. (2022). Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. International Journal of Molecular Sciences. 23(19). 11335–11335. 4 indexed citations
7.
Huang, Hsi‐Chien, Yun‐Chieh Sung, Chung‐Pin Li, et al.. (2021). Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours. Gut. 71(9). 1843–1855. 39 indexed citations
8.
9.
Wu, Chen‐Yi, et al.. (2020). Is rosacea a risk factor for cancer: A population-based cohort study in Taiwan. Dermatologica Sinica. 38(1). 15–15. 23 indexed citations
10.
Lee, I‐Cheng, Ya‐Wen Hung, Chien‐An Liu, et al.. (2019). A new ALBI‐based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver International. 39(9). 1704–1712. 76 indexed citations
11.
Lee, Pei‐Chang, Yee Chao, Teh‐Ia Huo, et al.. (2017). Validation of the albumin‐bilirubin grade‐based integrated model as a predictor for sorafenib‐failed hepatocellular carcinoma. Liver International. 38(2). 321–330. 35 indexed citations
12.
Chen, Ming‐Huang, Chung‐Pin Li, Yi‐Ping Hung, et al.. (2017). Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center. Journal of the Chinese Medical Association. 80(3). 140–146. 20 indexed citations
13.
Chen, Ming‐Huang, Johnson Lin, Chin‐Fu Hsiao, et al.. (2016). A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma. Medicine. 95(3). e2565–e2565. 32 indexed citations
14.
Lee, Wei‐Ping, Ming‐Chih Hou, Keng‐Hsin Lan, et al.. (2016). Helicobacter pylori-induced chronic inflammation causes telomere shortening of gastric mucosa by promoting PARP-1-mediated non-homologous end joining of DNA. Archives of Biochemistry and Biophysics. 606. 90–98. 23 indexed citations
15.
Wu, Chen‐Yi, Hsiao‐Yun Hu, Yiing‐Jenq Chou, et al.. (2015). High Blood Pressure and All-Cause and Cardiovascular Disease Mortalities in Community-Dwelling Older Adults. Medicine. 94(47). e2160–e2160. 136 indexed citations
16.
Kao, Wei‐Yu, Yee Chao, Chun‐Chao Chang, et al.. (2015). Prognosis of Early-Stage Hepatocellular Carcinoma. Medicine. 94(43). e1929–e1929. 32 indexed citations
17.
Hung, Hung-Hsu, Yee Chao, Yi‐You Chiou, et al.. (2014). A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child–Pugh Scores of 5 or 6. Medicine. 93(29). e348–e348. 15 indexed citations
18.
Infante, Jeffrey R., Bradley G. Somer, Joon Oh Park, et al.. (2014). A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer. 50(12). 2072–2081. 271 indexed citations
19.
20.
Parsi, Mansour A., Ang Li, Chung‐Pin Li, & Michael Goggins. (2008). DNA Methylation Alterations In Endoscopic Retrograde Cholangiopancreatography Brush Samples of Patients With Suspected Pancreaticobiliary Disease. Clinical Gastroenterology and Hepatology. 6(11). 1270–1278. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhenqiu Liu Breakdown of academic impact, for papers by Ioannis Ntanasis‐Stathopoulos Breakdown of academic impact, for papers by Bernd Kremer Breakdown of academic impact, for papers by Diamantis I. Tsilimigras Breakdown of academic impact, for papers by David L. Cutler Breakdown of academic impact, for papers by Dimitrios Moris Breakdown of academic impact, for papers by Hugh Mulcahy Breakdown of academic impact, for papers by Ardeshir Ghavamzadeh Breakdown of academic impact, for papers by Irene Helenowski Breakdown of academic impact, for papers by Emanuela Scarpi
Rankless by CCL
2026